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ited not only p110α but also its down-
stream effector, the protein kinase TOR. 
Broad inhibitory action was essential for 
shutting down the growth of glioma cells. 
However, in order to be effective, the pro-
miscuity of the drug had to be targeted to 
PI3K and TOR. Then, and only then, did 
vice become a virtue, with PI-103 achiev-
ing the effects of combination therapy as 
a single agent (Figure 1).
Specificity of target combination
Given the complexity of cellular signaling 
and the ability of cells to compensate for 
loss of function, it comes as no surprise 
that more than one kinase needs to be 
inhibited to achieve a significant change 
in the cellular phenotype. The effects on 
multiple targets need to be complemen-
tary and then are synergistic. The action 
of the new PI3K inhibitor lends support to 
a model of PI3K signaling that includes as 
an essential feature a negative feedback 
loop originating from TOR and targeting 
an upstream component of the signal-
ing chain (Hay, 2005; Wullschleger et al., 
2006). An inhibitor directed to TOR alone 
weakens this negative feedback and 
results in activation of the PI3K signaling 
pathway. Only the dual PI3K-TOR inhibi-
tor can prevent this compensatory effect 
(Figure 1) (Fan et al., 2006). Among the 
compounds tested, the inhibitor PI-103 
is also the most effective in reducing Akt 
phosphorylation. A particularly gratifying 
quality of the dual PI3K-TOR inhibitor PI-
103 is its lack of toxicity. This fact allays 
fears that PI3K inhibitors may induce 
intolerable side effects on essential cel-
lular activities such as insulin signaling. 
With the identification of p110α and TOR 
as a critical target combination in glioma, 
the stage is set for rapid progress in the 
field of PI3K inhibitors.
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Apoptosis that proceeds via the mitochondrial pathway involves mitochondrial outer membrane permeabilization (MOMP), 
responsible for the release of cytochrome c and other proteins of the mitochondrial intermembrane space. This essential 
step is controlled and mediated by proteins of the Bcl-2 family. The proapoptotic proteins Bax and Bak are required for MOMP, 
while the antiapoptotic Bcl-2 proteins, including Bcl-2, Bcl-xL, Mcl-1, and others, prevent MOMP. Different proapoptotic BH3-
only proteins act to interfere with the function of the antiapoptotic Bcl-2 members and/or activate Bax and Bak. Here, we 
discuss an emerging view, proposed by Certo et al. in this issue of Cancer Cell, on how these interactions result in MOMP 
and apoptosis.In his classic film Rashomon, Akira 
Kurosawa told the story of a samurai’s 
death from four distinct points of view and 
presented his rain-soaked protagonists, 
and us, with the changing nature of truth. 
In this issue of Cancer Cell, Certo et al. 
(2006) provide a new perspective on how 
cells die and provide a possible resolution 
to a controversy that focuses on the heart 
of this process, at the gates of death. As 
in Rashomon, we can find four different 
and perhaps not completely incompatible 328	viewpoints on how an important form of 
cell death occurs.
Most physiological cell deaths in 
animals occur through apoptosis, and 
most apoptosis in mammals proceeds 
by the mitochondrial pathway, wherein 
mitochondrial outer membrane permea-
bilization (MOMP) allows the proteins of 
the intermembrane space to diffuse into 
the cytosol (Green, 2005). MOMP is most 
likely a result of formation of a proteolipid 
pore, although this has not been visual-ized. Upon MOMP, holocytochrome c con-
tacts APAF-1, inducing the latter to recruit 
and activate caspase-9. Caspase-9 in turn 
cleaves and thereby activates executioner 
caspases, which then orchestrate apop-
tosis. Even without downstream caspase 
activation, however, MOMP appears to be 
sufficient to commit most cells to die, and 
death can proceed following MOMP in a 
caspase-independent manner. Therefore, 
MOMP is a critical decision point at which 
cell life and death is determined.cancer cell May	2006
	 p r e v i e w sFigure 1.	Four	versions	of	the	death	of	a	cell
a:	In	this	view,	Bax	and	Bak	(the	gate)	are	constitutively	active	on	the	surface	of	the	mitochondrial	outer	membrane	and	are	held	in	check	by	
the	antiapoptotic	Bcl-2	proteins	(the	tree).	a	lightning	strike	BH3-only	protein	neutralizes	this	inhibition,	releasing	Bax	and	Bak	to	permeabilize	the	
mitochondria,	and	death	proceeds.
B:	In	this	view,	Bax	and	Bak	are	inactive	unless	they	interact	with	“direct	activator”	BH3-only	proteins	such	as	Bid	and/or	Bim	(green	lightning).	
antiapoptotic	Bcl-2	proteins	can	prevent	this	activation,	and	are	in	turn	inhibited	by	other	BH3-only	proteins	that	act	as	“sensitizers”	or	“de-repres-
sors”	(purple	lightning).
c:	a	third	view,	wherein	only	cells	that	are	“primed	for	death”	sequester	direct	activator	BH3-only	proteins	on	antiapoptotic	Bcl-2	family	members.	
Sensitizer/de-repressor	BH3-only	proteins	displace	these	direct	activators,	which	now	activate	Bax	and	Bak	to	cause	MOMP	and	apoptosis.
D:	yet	another	view,	with	aspects	of	all	of	the	others,	where	cells	primed	for	death	sequester	not	only	Bid	and/or	Bim,	but	also	other	proteins	capa-
ble	of	activating	Bax	and	Bak.	alternatively,	physicochemical	conditions	in	cells	may	activate	Bax	and/or	Bak,	which	are	then	sequestered	by	
antiapoptotic	Bcl-2	proteins.	Sensitizer/de-repressor	BH3-only	proteins	release	the	sequestered	Bax	and	Bak,	or	the	proteins	that	activate	them,	
resulting	in	MOMP	and	apoptosis.MOMP is controlled by the members 
of the Bcl-2 family of proteins, defined 
by the sharing of from one to four Bcl-2 
homology (BH) domains. Two proapop-
totic multidomain (sharing BH1, -2, and 
-3) proteins, Bax and Bak, appear to be 
essential for MOMP (Wei et al., 2001) 
and probably directly form the pore in 
the outer membrane (Kuwana et al., 
2002). In the absence of Bax and Bak, 
MOMP does not occur, and such cells 
deprived of survival factors (a condi-
tion that normally promotes MOMP and 
apoptosis) instead undergo autophagy 
as a means of long-term survival (Lum 
et al., 2005). Antiapoptotic Bcl-2 pro-
teins prevent MOMP and promote cell 
survival. A third set of Bcl-2 proteins 
share only the BH3 domain and pro-
mote apoptosis, but the precise manner 
in which they do this is the controversy 
that concerns us here.cancer cell May	2006	The first version of how MOMP pro-
ceeds by the function of Bax and Bak 
proposes that these multidomain Bcl-2 
family proteins are constitutively active 
and are held in check by the antiapop-
totic Bcl-2 proteins (Chen et al., 2005) 
(Figure 1A). The BH3-only proteins 
neutralize the antiapoptotic proteins 
and release Bax and Bak, which cause 
MOMP, and death proceeds. However, 
because different antiapoptotic Bcl-
2 proteins are neutralized by different 
BH3-only proteins, death results only 
when all of the functional antiapoptotic 
Bcl-2 proteins are effectively targeted. In 
this “death by default” model, the pres-
ence of the right combination of BH3-
only proteins is necessary and sufficient 
for the decision to undergo apoptosis.
A second version of the story holds 
that Bax and Bak are not constitutively 
active but are activated by a subset of the BH3-only proteins (Letai et al., 2002; 
Kuwana et al., 2005) (Figure 1B). Two 
such “direct activators” have been identi-
fied, Bid and Bim, and either of these can 
trigger MOMP through activation of Bax 
and Bak. However, because antiapoptotic 
proteins can sequester these direct acti-
vator BH3-only proteins, neutralization of 
the antiapoptotic proteins may be neces-
sary for apoptosis to occur. Other BH3-
only proteins can perform this function, 
acting as “sensitizers” or “de-repressors” 
by neutralizing those antiapoptotic Bcl-
2 proteins they bind (Letai et al., 2002; 
Kuwana et al., 2005). Thus, BH3-only 
proteins not only differ in which other 
Bcl-2 proteins they interact with (differ-
ent antiapoptotic Bcl-2 proteins as well 
as Bax and Bak), but also perform differ-
ent functions. Without activation of Bax 
and/or Bak, the sensitizer/de-repressor 
BH3-only proteins do not trigger MOMP 329
	 p r e v i e w sand thus do not cause apoptosis. This is 
a “life by default” scenario.
Now, Letai and colleagues (Certo et 
al., 2006) offer a third view that may, at 
first blush, help to reconcile this controver-
sy. In agreement with other groups (Chen 
et al., 2005; Kuwana et al., 2005), they 
found that BH3-only proteins show diverse 
abilities to neutralize different antiapop-
totic Bcl-2 family members. In this view 
(Figure 1C), however, neutralization of 
antiapoptotic Bcl-2 proteins leads to death 
only in cells that have been stressed to 
engage the direct activators of Bax and 
Bak but are kept alive by one or more of 
the antiapoptotic Bcl-2 family members. In 
such cells the mitochondria are poised to 
undergo MOMP upon exposure to sensi-
tizer/de-repressor BH3-only proteins that 
neutralize the antiapoptotic proteins to 
which the cells have become “addicted.” 
Similarly, the Bcl-2/Bcl-xL inhibitor ABT-
737 (Oltersdorf et al., 2005) triggered 
apoptosis in growth factor-deprived cells 
sustained by Bcl-2, but not in the same 
cells maintained in their exogenous sur-
vival factor. Thus, BH3-only proteins that 
neutralize antiapoptotic Bcl-2 family mem-
bers will cause apoptosis only in some 
cells that are poised to die, and not in oth-
ers that do not require these antiapoptotic 
proteins to survive (as Bax and Bak are 
not activated).
This modified view of Bcl-2 function 
has direct implications for understand-
ing apoptosis regulation in oncogenesis 
and the use of Bcl-2 inhibitors in treat-
ing cancer. Oncogenes such as c-Myc, 
which drive cells into cycle, also engage 
Bax/Bak-dependent apoptosis (Dansen 
et al., 2006). Antiapoptotic Bcl-2 family 
members can prevent such cell death 
and thereby promote oncogenic transfor-
mation. In such cases, Bcl-2 antagonists 
should trigger MOMP and apoptosis, with-
out causing death in normal cells that are 
not so lethally poised. If so, then use of 
such agents holds promise for effective 
anticancer therapy, without the cost of 
widespread apoptosis of primary tissues.330	As attractive as this idea may be, a 
simple prediction is likely to undermine 
it. Of all BH3-only proteins examined, 
only Bid and Bim have the capacity 
to act as direct activators of Bax and 
Bak, to poise cells for MOMP and death 
upon antagonism of the antiapoptotic 
Bcl-2 proteins. This predicts that, in the 
absence of Bid and Bim, apoptosis will 
be as profoundly impaired as is seen 
in cells deficient in Bax and Bak. Early 
indications are that this is not the case 
(T. Kaufman, D. Huang, and A. Strasser, 
personal communication).
Are there additional ways in which 
Bax and Bak can be activated? Perhaps. 
A slight change in perspective brings in 
a fourth version of the story at the gates 
of death. While Bid and Bim are cur-
rently the only BH3-only proteins that 
are implicated in the activation of Bax 
and Bak, might there not be other ways 
these proteins can become activated? 
Recently, cytosolic p53 has been shown 
to have this potential, and like Bid and 
Bim, to be sequestered by antiapoptotic 
Bcl-2 proteins until released by a sen-
sitizer/de-repressor BH3-only protein, 
Puma (Chipuk et al., 2005). Other non-
Bcl-2 proteins may similarly have this 
activity. Or perhaps Bax and Bak can 
sometimes be directly activated by con-
ditions in the cell without a requirement 
for other proteins. Detergents have this 
effect experimentally, and mild heat may 
similarly directly activate Bax and Bak. 
If such activation is held in check by 
antiapoptotic Bcl-2 family proteins, then 
the basic concepts proposed by Letai 
et al. may be general. Some cells live 
under conditions where neutralization of 
antiapoptotic mechanisms causes death 
(“death by default”), while others live 
under conditions where such neutrali-
zation is not lethal (“life by default”).
Four slightly different perspectives, 
each with different consequences, each 
building on the story that precedes it. 
And each affecting our understanding of 
apoptosis and how it may apply to the treatment of cancers. Are any of these 
stories more than a flawed approxima-
tion of reality? We sit and wait out the 
rain, and puzzle over the truth at the 
gates of death. (Fade to black.)
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